Aspects of early arthritis - Biological therapy in early arthritis - overtreatment or the way to go?

被引:29
作者
Ikeda, Kei [1 ]
Cox, Sally [1 ]
Emery, Paul [1 ]
机构
[1] Univ Leeds, Chapel Allerton Hosp, Acad Unit Musculoskeletal Dis, Leeds LS7 4SA, W Yorkshire, England
关键词
D O I
10.1186/ar2177
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The availability of newer, and more expensive, therapies for patients with rheumatoid arthritis has changed treatment beyond recognition. Disease remission is the goal for all new patients. Studies have shown that a combination of tumour necrosis factor (TNF)-blocking drugs and methotrexate produces superior outcomes over monotherapy alone; however, use is limited by cost and potential side-effects. Currently, anti-TNF therapy is normally reserved for patients who have failed traditional disease-modifying anti-rheumatic drugs. The question that remains is whether TNF-blocking drugs are better used if given early; the high direct costs are countered by both direct and indirect savings in healthcare costs from optimal control of disease, and the benefits of early control outweigh the increased risk of infection and malignancy.
引用
收藏
页数:7
相关论文
共 63 条
[1]  
Anderson JJ, 2000, ARTHRITIS RHEUM, V43, P22, DOI 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO
[2]  
2-9
[3]   Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists [J].
Askling, J ;
Fored, CM ;
Baecklund, E ;
Brandt, L ;
Backlin, C ;
Ekbom, A ;
Sundström, C ;
Bertilsson, L ;
Cöster, L ;
Geborek, P ;
Jacobsson, LT ;
Lindblad, S ;
Lysholm, J ;
Rantapää-Dahlqvist, S ;
Saxne, T ;
Klareskog, L ;
Feltelius, N .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1414-1420
[4]   Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists [J].
Askling, J ;
Fored, CM ;
Brandt, L ;
Baecklund, E ;
Bertilsson, L ;
Feltelus, N ;
Cöster, L ;
Geborek, P ;
Jacobsson, LT ;
Lindblad, S ;
Lysholm, J ;
Rantapää-Dahlqvist, S ;
Saxne, T ;
Klareskog, L .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1421-1426
[5]  
BARTELDS GM, 2007, IN PRESS ANN RHEUM D
[6]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[7]  
Bejarano V, 2006, ARTHRITIS RHEUM, V54, P4037
[8]   Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].
Bongartz, T ;
Sutton, AJ ;
Sweeting, MJ ;
Buchan, I ;
Matteson, EL ;
Montori, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285
[9]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[10]  
Buch MH, 2003, ARTHRITIS RHEUM, V48, pS325